MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
4502.45%
Quick Ratio
4502.45%
Cash Ratio
3061.38%
Debt to Asset Ratio
2.76%
Unit: Thousand (K) dollars
Assets Breakdown
Cash and cash equivalents
Short-term marketable securities
Long term marketable securities
Others
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Operating lease liabilities, lon...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
165,896
36,626
35,021
32,496
Short-term marketable securities
74,232
67,913
78,103
84,197
Prepaid expenses and other current assets
3,860
3,177
3,280
2,787
Total current assets
243,988
107,716
116,404
119,480
Long term marketable securities
17,436
-
0
8,806
Operating lease right-of-use assets
1,951
39
78
115
Other assets
55
-
-
-
Total assets
263,430
107,755
116,482
128,401
Accounts payable
1,131
2,303
1,309
4,243
Accrued expenses and other current liabilities
4,204
2,955
3,714
4,788
Operating lease liabilities
84
39
78
115
Total current liabilities
5,419
5,297
5,101
9,146
Operating lease liabilities, long-term
1,856
-
-
-
Liabilities, total
7,275
-
-
-
Common stock-Common Class A
6
3
3
3
Common stock-Common Class B
0
0
0
0
Additional paid-in capital
627,178
459,446
457,607
455,916
Accumulated deficit
-370,952
-356,999
-346,349
-336,781
Accumulated other comprehensive (loss) income
-77
8
120
117
Total stockholders' equity
256,155
102,458
111,381
119,255
Total liabilities and stockholders' equity
263,430
107,755
116,482
128,401
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$165,896K
(291.94%↑ Y/Y)
Short-term marketable
securities
$74,232K
(-10.65%↓ Y/Y)
Prepaid expenses and
other current assets
$3,860K
(115.76%↑ Y/Y)
Total current assets
$243,988K
(91.82%↑ Y/Y)
Long term marketable
securities
$17,436K
(73.34%↑ Y/Y)
Operating lease
right-of-use assets
$1,951K
(1183.55%↑ Y/Y)
Other assets
$55K
Total assets
$263,430K
(91.72%↑ Y/Y)
Total liabilities and
stockholders' equity
$263,430K
(91.72%↑ Y/Y)
Total stockholders'
equity
$256,155K
(96.80%↑ Y/Y)
Liabilities, total
$7,275K
Accumulated deficit
-$370,952K
(-14.54%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$77K
(-201.32%↓ Y/Y)
Additional paid-in capital
$627,178K
(38.16%↑ Y/Y)
Total current
liabilities
$5,419K
(-25.22%↓ Y/Y)
Operating lease
liabilities, long-term
$1,856K
Common stock-Common
Class A
$6K
(100.00%↑ Y/Y)
Accrued expenses and
other current...
$4,204K
(-18.75%↓ Y/Y)
Accounts payable
$1,131K
(-41.12%↓ Y/Y)
Operating lease
liabilities
$84K
(-44.74%↓ Y/Y)
Buy us a coffee
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)